DelveInsight has launched a new report on Refractory Angina Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Refractory Angina market report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Refractory Angina treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Refractory Angina (RA) is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart.Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease(CAD).
Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causespoor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization. Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.
Request for :- Free sample page
Epidemiology
The Refractory Angina epidemiology division provide insights about historical and current Refractory Angina patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken
Report key facts:-
1. As per Delveinsight’s estimates, the total prevalent cases of Refractory Angina in 7 major markets ranges from 29,17,196 in 2017.
2. According to the Delveinsight’s analysts, the United States accounted for most prevalent cases of RA in 7MM with 19,05,602 cases in 2017.
3. Japan accounted for 27,432 cases in 2017 which are expected to grow during the study period (2017–2030).
Refractory Angina (RA)is a chronic disease characterized by the presence of persistent angina and patients with RA defined as being ‘no option’ since they are not considered amenable for conventional revascularization treatment for reasons related to diffuse coronary lesions, unsuitability to chronic total occlusion mechanical revascularization, or frailty from the presence of severe comorbidities
Key companies working on Refractory Angina that are given below:-
1. Imbria Pharmaceuticals
2. Caladrius Biosciences, Inc
3. XyloCor Therapeutics, Inc
Name of drugs covered that are given below:-
1. IMB-101
2. Auto CD34+ Cells
3. XC001
1. Key Insights
2. Executive Summary of Refractory Angina
3. Competitive Intelligence Analysis for Refractory Angina
4. Refractory Angina: Market Overview at a Glance
4.1. Refractory Angina Total Market Share (%) Distribution in 2017
4.2. Refractory Angina Total Market Share (%) Distribution in 2030
5. Refractory Angina: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Refractory Angina Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Refractory Angina Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Refractory Angina Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Refractory Angina Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Refractory Angina Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Refractory Angina Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Refractory Angina Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Refractory Angina Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Refractory Angina Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Refractory Angina Treatment and Management
8.2. Refractory Angina Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Refractory Angina Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Refractory Angina: Seven Major Market Analysis
13.1. Key Findings
13.2. Refractory Angina Market Size in 7MM
13.3. Refractory Angina Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Refractory Angina Total Market Size in the United States
15.1.2. Refractory Angina Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Refractory Angina Total Market Size in Germany
15.3.2. Refractory Angina Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Refractory Angina Total Market Size in France
15.4.2. Refractory Angina Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Refractory Angina Total Market Size in Italy
15.5.2. Refractory Angina Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Refractory Angina Total Market Size in Spain
15.6.2. Refractory Angina Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Refractory Angina Total Market Size in the United Kingdom
15.7.2. Refractory Angina Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Refractory Angina Total Market Size in Japan
15.8.3. Refractory Angina Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Refractory Angina
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market
- To understand the future market competition in the Refractory Angina market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina market
- To understand the future market competition in the Refractory Angina market
Related Reports:-
1. Relapsed or Refractory Mycosis Fungoides – Epidemiology Forecast to 2030
2. relapsed/refractory Epstein-Barr virus (EBV) – Epidemiology Forecast to 2030
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/